sulfonylurea


Also found in: Dictionary, Medical, Wikipedia.
Related to sulfonylurea: metformin, Biguanides, Sulfonylurea receptor
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to sulfonylurea

antidiabetic consisting of any of several drugs that reduce the level of glucose in the blood

References in periodicals archive ?
For patients who cannot tolerate or have contraindications to metformin, a sulfonylurea is often prescribed as first-line therapy for type 2 diabetes," said Kathleen Dungan, M.
The recently published results, which were included in the company's New Drug Application approved by the FDA in June 2005, were generated from the randomized, double-blind Phase 3 clinical trial comparing treatment with regimens of Glumetza and sulfonylurea combination therapy to a regimen of sulfonylurea monotherapy in patients with Type 2 diabetes.
Cardiovascular disease (CVD) events also happened sooner among the sulfonylurea patients, said Ying Qui, Ph.
Patients who received linagliptin as add-on to metformin and sulfonylurea with baseline HbA1c greater than or equal to 7.
Among the survey respondents who received oral medications, 52% reported receiving sulfonylureas.
The PPAR-gamma agonists, Januvia and Amylin/Eli Lilly's Byetta are each competing for positioning in second- and third-line therapy because of the dominance of generic metformin and sulfonylureas in earlier lines of treatment.
These active ingredients included sulfonylurea, dicamba, atrazine, and mesotrione alone or in combination with other herbicides.
The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
BYETTA is indicated for use as an adjunctive therapy for people with type 2 diabetes who are not achieving blood sugar control using metformin, a sulfonylurea, or a thiazolidinedione.
In the prospective, multicenter, open-label Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD) trial, funded by Glaxo-SmithKline, the addition of rosiglitazone (Avandia) to either sulfonylurea or metformin therapy in people with type 2 diabetes increased their risk for heart failure but did not increase the risk of overall cardiovascular morbidity or mortality in a mean follow-up of 5.
CHICAGO, June 24 /PRNewswire-FirstCall/ -- New findings from a retrospective cohort study using real-world claims data of more than 15,000 drug naive patients with type 2 diabetes showed that initial therapy with Avandia(R) (rosiglitazone maleate) was associated with significantly fewer healthcare visits and lower total medical costs when compared to patients initiating therapy with a sulfonylurea.
Teva's Glipizide and Metformin Hydrochloride Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Metaglip(R) Tablets, which are indicated as an adjunct to diet and exercise in type 2 diabetes, as initial therapy or as a second-line therapy when response to sulfonylurea or metformin is inadequate.
5% but still above 7%, either insulin or a sulfonylurea may be added.
In the OAD group, 16% of patients were treated with metformin plus sulfonylurea, 27% with a sulfonylurea alone, and 8% with sulfonylurea and a DPP-4 inhibitor.
As an insulin secretagogue, sulfonylurea directly acts on sulfonylurea receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar's excitation upon insulin release.